Director boosts stake as Teva (TEVA) RSUs vest into ordinary shares

Rhea-AI Filing Summary

Teva Pharmaceutical Industries director Gerald M. Lieberman exercised restricted share units into ordinary shares. On June 5, 2026, he acquired 14,492 ordinary shares at a stated price of $0.00 per share through the vesting and conversion of restricted share units granted on June 5, 2025.

Following this transaction, he directly holds 130,149 ordinary shares. The footnotes note that each restricted share unit entitled him, at settlement, to receive one ordinary share or the cash value of one ordinary share, and that ordinary shares may be represented by American Depositary Shares on a one-for-one basis.

Insider Trade Summary

14,492 shares exercised/converted

Mixed 2 txns

Insider LIEBERMAN GERALD M

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	14,492	$0.00	--
Exercise	Ordinary Shares	14,492	$0.00	--

Holdings After Transaction: Restricted Share Units — 0 shares (Direct, null); Ordinary Shares — 130,149 shares (Direct, null)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

Key Figures

Shares acquired via RSU exercise: 14,492 shares Shares held after transaction: 130,149 shares RSU grant date: June 5, 2025 +2 more

5 metrics

Shares acquired via RSU exercise 14,492 shares Ordinary shares received on June 5, 2026

Shares held after transaction 130,149 shares Direct holdings following June 5, 2026 transaction

RSU grant date June 5, 2025 Restricted share units originally granted

RSU vesting date June 5, 2026 Restricted share units vested and converted

Stated exercise price $0.00 per share Conversion of restricted share units into ordinary shares

Key Terms

Restricted Share Units, American Depositary Shares, contingent right

3 terms

Restricted Share Units financial

"security_title: "Restricted Share Units" and footnote describing each unit as a contingent right"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

contingent right financial

"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or the cash value of one ordinary share."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LIEBERMAN GERALD M

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV ISRAEL 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/05/2026		M		14,492	A	(2)	130,149	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	06/05/2026		M			14,492	(3)	(3)	Ordinary Shares(1)	14,492	$0	0	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

	/s/ Dov Bergwerk as attorney-in-fact for Gerald M. Lieberman	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Teva (TEVA) disclose for Gerald M. Lieberman?

Teva disclosed that director Gerald M. Lieberman exercised restricted share units into 14,492 ordinary shares on June 5, 2026. This was a derivative exercise, not an open‑market purchase or sale, and increased his directly held ordinary share position.

How many Teva (TEVA) shares does Gerald M. Lieberman hold after this Form 4?

After the June 5, 2026 transaction, Gerald M. Lieberman holds 130,149 Teva ordinary shares directly. This reflects the addition of 14,492 shares received upon the vesting and conversion of previously granted restricted share units reported in the filing.

Was there any open-market buying or selling in this Teva (TEVA) Form 4?

No open‑market buying or selling occurred. The Form 4 shows an exercise of restricted share units into 14,492 ordinary shares at a stated price of $0.00 per share, with no separate sale transaction reported in connection with this event.

What do the restricted share units reported by Teva (TEVA) represent?

Each restricted share unit represented a contingent right to receive, at settlement, one Teva ordinary share or the cash value of one ordinary share. In this case, the units vested and were settled in 14,492 ordinary shares credited to the director.

When were the Teva (TEVA) restricted share units granted and when did they vest?

The restricted share units were granted on June 5, 2025 and vested on June 5, 2026. Upon vesting, they were converted into 14,492 ordinary shares, which are now included in Gerald M. Lieberman’s directly held Teva share position.

How are Teva (TEVA) ordinary shares related to American Depositary Shares?

According to the footnotes, Teva’s ordinary shares may be represented by American Depositary Shares, with each American Depositary Share currently representing one ordinary share. This means the economic interest per share is aligned on a one‑for‑one basis.